Literature DB >> 20430036

Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin.

Andreas Bültmann1, Zhongmin Li, Silvia Wagner, Mario Peluso, Tanja Schönberger, Carla Weis, Ildiko Konrad, Konstantinos Stellos, Steffen Massberg, Bernhard Nieswandt, Meinrad Gawaz, Martin Ungerer, Götz Münch.   

Abstract

Glycoprotein VI (GPVI) mediates binding of platelets to subendothelial collagen during acute arterial thrombosis. GPVI interactions with the activated atherosclerotic vascular endothelium during early atherosclerosis, however, are not well understood. In ApoE-/- mice, platelet adhesion to atherosclerotic arteries was increased, as measured by intravital microscopy. This platelet adhesion was significantly inhibited by IV injection of GPVI-Fc (1 mg/kg body weight). Atherosclerosis in ApoE-/- mice was attenuated both after 7 and 10 weeks of treatment with the anti-GPVI antibody JAQ1 (2 mg/kg body weight i.p. twice weekly). Binding of GPVI-Fc (1 mg/kg IV) occurred to deeper layers, but also to the luminal site of plaques in atherosclerotic rabbits, but not to the vessel wall of healthy littermates. Gene transfer of GPVI-Fc to the carotid vascular wall significantly attenuated athero-progression and endothelial dysfunction in atherosclerotic rabbits in vivo. Specific binding of the soluble GPVI receptor (GPVI-Fc) to fibronectin was found in vitro to coated ELISA plates. Platelet adhesion to fibronectin was significantly inhibited both by GPVI-Fc and by the anti-GPVI antibody 5C4 ex vivo in flow chamber experiments. GPVI plays a role in platelet adhesion to atherosclerotic endothelium in the absence of plaque rupture. Inhibition of GPVI both via GPVI-Fc and anti-GPVI-antibodies results in protection against atherosclerosis in both cholesterol-fed rabbits and ApoE-/- mice. This novel mechanism of GPVI-mediated platelet adhesion-possibly via fibronectin-could relevantly contribute to platelet-triggered atheroprogression. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20430036     DOI: 10.1016/j.yjmcc.2010.04.009

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  29 in total

Review 1.  Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.

Authors:  J J Shatzel; S R Olson; D L Tao; O J T McCarty; A V Danilov; T G DeLoughery
Journal:  J Thromb Haemost       Date:  2017-03-27       Impact factor: 5.824

Review 2.  Platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling and vascular integrity.

Authors:  Yacine Boulaftali; Paul R Hess; Mark L Kahn; Wolfgang Bergmeier
Journal:  Circ Res       Date:  2014-03-28       Impact factor: 17.367

3.  Proteins, platelets, and blood coagulation at biomaterial interfaces.

Authors:  Li-Chong Xu; James W Bauer; Christopher A Siedlecki
Journal:  Colloids Surf B Biointerfaces       Date:  2014-09-28       Impact factor: 5.268

4.  Genomewide linkage and peakwide association analyses of carotid plaque in Caribbean Hispanics.

Authors:  Chuanhui Dong; Ashley Beecham; Susan Slifer; Liyong Wang; Susan H Blanton; Clinton B Wright; Tatjana Rundek; Ralph L Sacco
Journal:  Stroke       Date:  2010-10-21       Impact factor: 7.914

Review 5.  Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases.

Authors:  Dan Li; Yujuan Li; Shengjie Yang; Zongliang Yu; Yanwei Xing; Min Wu
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 6.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

7.  Soluble fibrin causes an acquired platelet glycoprotein VI signaling defect: implications for coagulopathy.

Authors:  M Y Lee; C C Verni; B A Herbig; S L Diamond
Journal:  J Thromb Haemost       Date:  2017-10-27       Impact factor: 5.824

8.  The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times.

Authors:  Martin Ungerer; Zhongmin Li; Christine Baumgartner; Silvia Goebel; Jasmin Vogelmann; Hans-Peter Holthoff; Meinrad Gawaz; Götz Münch
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

9.  The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.

Authors:  Silvia Goebel; Zhongmin Li; Jasmin Vogelmann; Hans-Peter Holthoff; Heidrun Degen; Dirk M Hermann; Meinrad Gawaz; Martin Ungerer; Götz Münch
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits.

Authors:  Götz Münch; Andreas Bültmann; Zhongmin Li; Hans-Peter Holthoff; Julia Ullrich; Silvia Wagner; Martin Ungerer
Journal:  Heart Int       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.